AASLD Announces New Class of Fellows

AASLD is pleased to announce the selection of twenty-four hepatology leaders as Fellows and one allied health leader focused on hepatology as an Associate Fellow. The Fellows Programs bestows honorary recognition upon AASLD members who have made a significant contribution to the knowledge and/or practice of liver and biliary diseases, and are considered leaders in the field. AASLD Fellows and

AASLD 2022 Capitol Hill Day Recap

On March 23, AASLD held its annual Liver Capitol Hill Day. For the third time since the beginning of the COVID-19 pandemic, this year’s LCHD was conducted online. Bringing together 45 participants, including AASLD members, patient advocates, Emerging Liver Scholars, and society staff. Participants joined 53 meaningful conversations on AASLD’s priorities with members of Congress and their staff

GI Societies Vote No On ANSI/AAMI Revisions On Endoscopic Processing

Changes to ST91 for Flexible and Semi-Rigid Endoscopes Create Obstacles to Implement Standards and Offer Impractical, Inappropriate or Conflicting Guidance AASLD, ACG, AGA, ASCRS, ASGE, SAGES and SGNA are committed to initiatives focused on eliminating healthcare-associated infections through improved education about evidence-based practices. While our societies appreciated the opportunity to

Coming Soon: New Funding Program for Early-Career APPs from AASLD Foundation

A new program for early career and new-to-hepatology Advanced Practice Providers will launch this spring with the goal of strengthening the liver provider pipeline and fostering the next generation of APP leaders in hepatology. “Since 2004, AASLD Foundation (originally through AASLD) has provided over $10.4 million to support APP specialized training through the NP/PA Clinical Hepatology

In Memoriam - Dr. Joseph (Joe) R. Bloomer, MD, FACP, FAASLD

AASLD acknowledges the passing of esteemed member and fellow, Joseph R. Bloomer, MD, FACP, FAASLD. Dr. Bloomer was a distinguished physician-scientist and leader in the study of liver disease. He passed away on December 22, 2021, from complications related to Alzheimer's Disease. A widely acclaimed teacher, accomplished researcher, and compassionate clinician, Dr. Bloomer was Director of the UAB

Dr. DeLeve President's Welcome

For those of you who may not know me, I’m Laurie DeLeve, AASLD’s 73rd president. Once upon a very long time ago, my then-toddler told her teacher I am a mouse doctor. I am a physician-scientist doing basic research at USC. More importantly, since 1997, except for one single year, I have always been on an at least one AASLD committee, SIG or in a leadership position. I love the spirit, camaraderie

Reaching Consensus on NAFLD Nomenclature

There has been much progress regarding the ongoing discussions over nomenclature for nonalcoholic fatty liver disease (NAFLD). AASLD has been leading and participating in a global multi-stakeholder process that includes extensive involvement from patient groups to examine the options and ramifications around nomenclature in this condition. This nomenclature task force includes representatives from

AASLD Leaders Go To Washington (Virtually)

Often in this space, we discuss the advocacy efforts of AASLD with regard to the Congress, focusing on important authorizing and funding legislation pending and our efforts to advance it for the benefit of liver patients and AASLD members. But enacting laws in only one part of the equation. Those laws must be implemented, which is the responsibility of the Executive Branch. During December and

AASLD Remembers Hugo Ramon Rosen, MD, FAASLD

The American Association for the Study of Liver Diseases (AASLD) acknowledges the passing of Hugo Ramon Rosen, MD, FAASLD. Dr. Rosen passed away December 28, 2021. He was a prolific physician-scientist and liver immunologist with important contributions to the field of Hepatitis C Research. He served on the board of directors of the American Society of Transplantation and was honored with the

Progress In A Pandemic: The Year In Review

BY RAYMOND CHUNG, MD, FAASLD AASLD PRESIDENT As the pandemic entered its second year, 2021 continued to test and challenge us all. Challenges notwithstanding, I am thrilled to report that as a society, AASLD continued to accomplish great things and has made good on the objectives originally laid out in our strategic plan in 2018. I want to describe several of our most important accomplishments

AASLD Remembers Seymour M. Sabesin, MD, FAASLD

The American Association for the Study of Liver Diseases (AASLD) was recently notified that one of our esteemed members, Seymour Sabesin, MD, FAASLD, passed away on January 4, 2021. Dr. Sabesin was a distinguished gastroenterologist, serving as a Clinical and Research Associate at the National Institute of Health in Bethesda, MD followed by a residency at The New York Hospital-Cornell Medical

Major New Health Bill Is Introduced in Congress

Recently, Reps. Diana DeGette (D-CO) and Fred Upton (R-MI) introduced a bill that is universally known as “Cures 2.0.” The bill is the next iteration of legislation passed in 2016 called the 21st Century Cures Act. AASLD has been following the development of this legislation closely since the sponsors began discussions of it in 2019. The bill is 173 pages long and we cannot do justice to all its

Meet Dr. Noelle Ebel, 2021 Leonard B. Seeff Award Recipient

Dr. Noelle Ebel, recipient of the 2021 Leonard B. Seeff Award for Outstanding Research by an Early Career Investigator, was part of a team that created the largest North American registry for COVID-19 infection in children with liver transplants. Dr. Ebel will present her award-winning research this Monday, November 15th during Parallel 31: Clinical/ Translational Research in Pediatric Hepatology

Improved Center-specific Practices May Ease Effects Of Socioeconomic Deprivation For Pediatric Liver Transplant Recipients

Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that while neighborhood socioeconomic deprivation is associated with worse adverse long-term outcomes after liver transplant in children, improving center-specific practices can mitigate these effects for young at-risk patients.